United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by State of Michigan Retirement System
State of Michigan Retirement System lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 1,182.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 156,493 shares of the biotechnology company’s stock after acquiring an additional 144,293 shares during the quarter. State of Michigan Retirement System owned 0.36% of United Therapeutics worth $18,936,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of the company. Amundi Pioneer Asset Management Inc. lifted its holdings in shares of United Therapeutics by 18.8% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 76,221 shares of the biotechnology company’s stock worth $8,945,000 after purchasing an additional 12,087 shares during the last quarter. Guggenheim Capital LLC raised its stake in United Therapeutics by 27.7% during the 4th quarter. Guggenheim Capital LLC now owns 69,076 shares of the biotechnology company’s stock valued at $6,084,000 after acquiring an additional 14,980 shares in the last quarter. Bank of America Corp DE raised its stake in United Therapeutics by 75.3% during the 4th quarter. Bank of America Corp DE now owns 193,101 shares of the biotechnology company’s stock valued at $17,008,000 after acquiring an additional 82,925 shares in the last quarter. Janus Henderson Group PLC raised its stake in United Therapeutics by 50.3% during the 4th quarter. Janus Henderson Group PLC now owns 7,473 shares of the biotechnology company’s stock valued at $658,000 after acquiring an additional 2,501 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in United Therapeutics by 3.2% during the 4th quarter. Alliancebernstein L.P. now owns 75,319 shares of the biotechnology company’s stock valued at $6,634,000 after acquiring an additional 2,370 shares in the last quarter. Institutional investors own 97.99% of the company’s stock.
In other news, Director Tommy G. Thompson sold 3,100 shares of United Therapeutics stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $112.56, for a total transaction of $348,936.00. Following the transaction, the director now owns 9,050 shares in the company, valued at $1,018,668. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Raymond Dwek sold 4,600 shares of United Therapeutics stock in a transaction on Monday, June 29th. The shares were sold at an average price of $116.81, for a total value of $537,326.00. Following the transaction, the director now owns 4,600 shares in the company, valued at approximately $537,326. The disclosure for this sale can be found here. Insiders have sold 242,210 shares of company stock worth $28,840,232 in the last 90 days. 10.90% of the stock is owned by company insiders.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $2.41 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.41. United Therapeutics had a return on equity of 14.90% and a net margin of 30.04%. The firm had revenue of $362.00 million for the quarter, compared to the consensus estimate of $339.97 million. During the same quarter in the previous year, the company earned $3.63 EPS. The business’s revenue for the quarter was down 3.1% compared to the same quarter last year. As a group, research analysts anticipate that United Therapeutics Co. will post 10.4 EPS for the current year.
UTHR has been the topic of several recent analyst reports. Oppenheimer lifted their target price on United Therapeutics from $155.00 to $165.00 and gave the company an “outperform” rating in a research note on Thursday. TheStreet downgraded United Therapeutics from a “b” rating to a “c” rating in a research note on Wednesday. Cowen reaffirmed a “buy” rating and set a $145.00 target price on shares of United Therapeutics in a research note on Friday, June 12th. ValuEngine downgraded United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 2nd. Finally, Credit Suisse Group boosted their price objective on United Therapeutics from $129.00 to $145.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. United Therapeutics currently has an average rating of “Hold” and an average price target of $138.10.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Story: Stock Market – What is a circuit breaker?
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.